ArticleNeuroradiology2026
Multimodal integration of radiomics, pathomics, and clinical data enhances grading of adult diffuse gliomas using machine learning.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeAdult diffuse gliomas exhibit marked heterogeneity, making comprehensive evaluation of their biological behavior difficult. This study aimed to develop and validate a multimodal machine learning framework that fuses MRI-based radiomic features, whole-slide image (WSI)-derived pathomic signatures, and clinical variables for the comprehensive assessment of adult diffuse gliomas.
methodsRadiomic features were extracted from multiparametric MRI, and pathomic features from hematoxylin-eosin (H&E) stained WSIs; both were combined with clinical variables (age, sex, tumor dimensions, anatomical location). Unimodal radiomic/pathomic models and multimodal integrated models were built using three machine learning algorithms: random forest (RF), support vector machine (SVM), and eXtreme Gradient Boosting (XGBoost).
resultsA retrospective cohort of 373 pathologically confirmed patients was used for model construction and internal validation, with an independent external cohort of 49 patients for external validation. 40 radiomic and 20 pathomic features were retained via statistical testing and RF-based feature ranking. The optimal unimodal radiomic and pathomic models achieved internal validation AUCs of 0.89 and 0.83, respectively. The multimodal model showed superior performance (internal AUC = 0.90) and stable generalizability in external validation (AUC = 0.93). The multimodal model achieved AUC 0.93 with higher balanced accuracy and sensitivity. DeLong tests showed no statistically significant difference between multimodal and radiomics (P = 0.377) or pathomics (P = 0.085) in internal test; however, the multimodal model showed clinically meaningful improvements in sensitivity and balanced accuracy.
conclusionThe developed and validated multimodal machine learning model integrating radiomics, pathomics, and clinical information exhibits stable and reliable performance for the grading assessment of adult diffuse gliomas.
Indexed as
Identifiers
42154019What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.